Caxton Corporation’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Caxton Corporation’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-232,426	Closed	-$3.38M	–	20
2020 Q1	$3.38M	Hold	232,426	–	–	3.69%	7
2019 Q4	$2.75M	Buy	232,426 +79,688	+52%	+$1.33M	2.65%	9
2019 Q3	$3.85M	Buy	152,738 +77,143	+102%	+$2.23M	4.49%	9
2019 Q2	$1.92M	Buy	75,595 +67,674	+854%	+$2.62M	2.18%	11
2019 Q1	$337K	Buy	+7,921	New	+$179K	0.31%	14
2018 Q4	–	Sell	-3,178	Closed	-$222K	–	31
2018 Q3	$222K	Buy	3,178 +1,786	+128%	+$136K	0.24%	26
2018 Q2	$103K	Buy	+1,392	New	+$124K	0.11%	22
2015 Q3	–	Sell	-228	Closed	-$144K	–	24
2015 Q2	$144K	Buy	+228	New	+$121K	0.15%	18

Other funds holding VIRX

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return